Rosario in Paris says the team's four AI-designed peptides looked right on paper but none reached the binding affinity they wanted, ending work begun in February.
Recap by typeshit. Post by Rosario in Paris ᥫ᭡ on X.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
8:51
Regan Archibald takes on a common question from people using retatrutide: whether the tiredness some report wears off.
The retatrutide rival from United Biotechnology led to weight loss of up to 9.8% at 24 weeks in 211 Chinese adults, beating semaglutide's 4.8%, per Cell Metabolism.
Loading…